Announcement • May 31
Financial Conduct Authority Cancels the Listing of Mediclinic Shares on the London Stock Exchange and Delisting of Shares from the JSE and the NSX Expects to Take Effect on 7 June 2023 Further to the announcement made by Mediclinic International plc (Mediclinic) on 26 May 2023 that the Scheme has become Effective in accordance with its terms, Mediclinic announced that, following an application by Mediclinic, the Financial Conduct Authority (FCA) has cancelled the listing of Mediclinic Shares on the premium listing segment of the Official List and the London Stock Exchange (LSE) has cancelled the trading of Mediclinic Shares on the London Stock Exchange's main market for listed securities, in each case with effect from 8:00 a.m. (London time) 30 May 2023 . Following the suspension of Mediclinic Shares on the Main Board of the JSE and the NSX, effective from 9:00 a.m. (SAST) on commencement of trade on 26 May 2023, the delisting of Mediclinic Shares from the JSE and the NSX is expected to take effect from commencement of trade on 7 June 2023, being the first SA Business Day immediately following the date on which accounts are expected to be credited with the Consideration. Announcement • May 27
Mediclinic International's Cancellation of Shares from Official List and Main Market of LSE Expected to Take on 30 May 2023; Delisting of Shares from JSE and NSX Expected to Take Effect from Commencement of Trade on 7 June 2023 On 4 August 2022, the boards of directors of Mediclinic International plc (Mediclinic or the Company) (excluding the Remgro representative), Manta Bidco Limited (Bidco), Remgro and SAS announced that they had reached agreement on the terms of a recommended cash offer by Bidco for the entire issued and to be issued share capital of Mediclinic (the "Acquisition"), other than the Mediclinic Shares already owned by the Relevant Remgro Subsidiaries, to be implemented by way of a court sanctioned scheme of arrangement under Part 26 of the Companies Act (Scheme). The circular in relation to the Scheme (Scheme Document) was published and posted to Mediclinic Shareholders on 30 August 2022. The listing of Mediclinic Shares on the premium listing segment of the Official List of the Financial Conduct Authority and the admission to trading of Mediclinic Shares on the London Stock Exchange's main market for listed securities were suspended with effect from 7.30 a.m. (London time) on 26 May 2023. Dealings in Mediclinic Shares on the JSE and NSX were suspended with effect from 9.00 a.m. (SAST) on 26 May 2023. Applications have been made to the Financial Conduct Authority and the London Stock Exchange in relation to the de-listing of Mediclinic Shares from the premium listing segment of the Official List and the cancellation of the admission to trading of Mediclinic Shares on the London Stock Exchange's (LSE) main market for listed securities, which is expected to take place by 8:00 a.m. (London time) on 30 May 2023. It is expected that, subject to the approval of the Executive Committee of the JSE, the JSE will initiate the termination of the secondary listing of Mediclinic Shares on the Main Board of the JSE, in terms of paragraphs 1.12 and 1.13 of the JSE Listings Requirements, to take effect following May 26, 2023 (being the Effective Date) on the basis that Mediclinic no longer complies with the public spread provisions pursuant to paragraph 4.28(e) of the JSE Listings Requirements. The delisting of Mediclinic Shares on the NSX will occur simultaneously with the termination of the listing and trading of such shares from the JSE. The delisting of Mediclinic Shares from the JSE and the NSX is expected to take effect from commencement of trade on 7 June 2023, being the first SA Business Day immediately following the date on which accounts are expected to be credited with the Consideration. Announcement • May 26
Mediclinic International plc(LSE:MDC) dropped from FTSE 350 (Ex Investment Companies) Index (GBP) Mediclinic International plc(LSE:MDC) dropped from FTSE 350 (Ex Investment Companies) Index (GBP) 
